View of Immuno-oncology therapy and COVID-19: What are the potential benefits and risks of undergoing immune checkpoint inhibitor-based therapy for advanced non-small cell lung cancer during a COVID-19 pandemic? | Morecambe Bay Medical Journal

← Immuno-oncology therapy and COVID-19: What are the potential benefits and risks of undergoing immune checkpoint inhibitor-based therapy for advanced non-small cell lung cancer during a COVID-19 pandemic?